Healthcare Services

Global Anaplastic Astrocytoma Market Global Report 2026 Market Set for Strong Expansion Reaching $0.64 Billion by 2030 at 7% CAGR

March 30, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Forecasted Market Value Of The Anaplastic Astrocytoma Market Across 2026–2030?

The anaplastic astrocytoma market size has exhibited strong growth in recent years. It is anticipated to expand from $0.46 billion in 2025 to $0.49 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.1%. Factors contributing to its historical growth include improvements in brain tumor diagnostics, the availability of neurosurgical treatment options, the expansion of oncology treatment centers, growing clinical trial participation, and the increased use of radiotherapy.

The anaplastic astrocytoma market is anticipated to experience robust expansion over the coming years. Its valuation is projected to reach $0.64 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.0%. This anticipated growth during the forecast period is attributable to several factors, including heightened investments in neuro-oncology research, the growing acceptance of precision medicine methodologies, the broadening scope of targeted and adjunct treatments, an increased emphasis on early detection techniques, and stronger partnerships among research organizations. Key trends for the forecast duration encompass the increasing uptake of multimodal treatment methods, the expanded utilization of sophisticated neuroimaging instruments, a heightened emphasis on individualized oncology therapies, the broadening of clinical research endeavors, and improved integration of surgical and radiotherapy procedures.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12874&type=smp

What Drivers Are Shaping The Future Growth Of The Anaplastic Astrocytoma Market?

The increasing occurrence of primary malignant and non-malignant brain tumors is projected to boost the expansion of the anaplastic astrocytoma market. Brain tumors represent masses within the brain, categorized as either malignant (cancerous and invasive) or benign (non-cancerous and non-invasive), exhibiting diverse levels of aggressiveness and capacity for dissemination. Treatment for anaplastic astrocytoma involves excising the tumor along with adjacent affected tissue, all while maintaining brain function. As an illustration, the American Society of Clinical Oncology (ASCO), a non-profit organization based in the US, reported in March 2023 that an estimated 24,810 adults in the United States are anticipated to be diagnosed with primary cancerous tumors originating in the brain and spinal cord, comprising 14,280 cases among men and 10,530 among women. Consequently, the rising occurrence of primary malignant and non-malignant brain tumors is set to fuel the future expansion of the anaplastic astrocytoma market.

What Segmentation Levels Are Considered In The Anaplastic Astrocytoma Market?

The anaplastic astrocytoma market covered in this report is segmented –

1) By Treatment Type: Surgery, Chemotherapy, Radiation Therapy

2) By Route of Administration: Oral, Parenteral

3) By End User: Hospitals, Specialty Cancer Centers

Subsegments:

1) By Surgery: Maximal Safe Tumor Resection, Stereotactic Biopsy

2) By Chemotherapy: Alkylating Agents, Targeted Therapy

3) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Intensity-Modulated Radiation Therapy (IMRT)

What Trends Are Projected To Affect The Anaplastic Astrocytoma Market?

Leading companies in the anaplastic astrocytoma market are concentrating on developing advanced combination therapies to improve overall survival and progression-free survival in patients with recurrent disease. This approach involves using two or more drugs to simultaneously target cancer pathways, thereby enhancing treatment efficacy and reducing tumor progression. For example, in November 2024, Orbus Therapeutics, a US-based biopharmaceutical company, introduced a combination of eflornithine and lomustine within its Phase 3 STELLAR study. This therapy has shown clinically significant improvements in overall survival and progression-free survival for patients with grade 3 IDH mutant astrocytoma. Its prominent features include a median overall survival of 34.9 months, contrasted with 23.5 months for lomustine alone, a median progression-free survival of 15.8 months versus 7.2 months, and a generally well-tolerated safety profile. The treatment harnesses eflornithine’s capacity to irreversibly inhibit ornithine decarboxylase, a vital enzyme in polyamine biosynthesis, thereby boosting its cytostatic effect. The study encompassed over 343 patients across North America and Europe, demonstrating considerable clinical benefit in a difficult-to-treat population and presenting a promising new choice for patients suffering from recurrent anaplastic astrocytoma.

Which Leading Firms Are Contributing To The Growth Of The Anaplastic Astrocytoma Market?

Major companies operating in the anaplastic astrocytoma market are Pfizer Inc., Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Bristol Myers Squibb, AstraZeneca, Eli Lilly and Company, Johnson & Johnson, Eisai Co. Ltd, AbbVie Inc., Bayer AG, Amgen Inc., Ipsen SA, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Cipla Limited, Sun Pharmaceutical Industries Ltd., Dr Reddy’s Laboratories Ltd., Novocure Ltd., Celldex Therapeutics Inc.

Read the full anaplastic astrocytoma market report here:

https://www.thebusinessresearchcompany.com/report/anaplastic-astrocytoma-global-market-report

Which Geographic Regions Are Influencing Demand In The Anaplastic Astrocytoma Market?

North America was the largest region in the anaplastic astrocytoma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anaplastic astrocytoma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Anaplastic Astrocytoma Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12874&type=smp

Browse Through More Reports Similar to the Global Anaplastic Astrocytoma Market 2026, By The Business Research Company

anaplastic astrocytoma global market report

https://www.thebusinessresearchcompany.com/report/anaplastic-astrocytoma-global-market-report

anaplastic astrocytoma global market report

https://www.thebusinessresearchcompany.com/report/anaplastic-astrocytoma-global-market-report

paraganglioma global market report

https://www.thebusinessresearchcompany.com/report/paraganglioma-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795